Alex Wyatt

Here’s our @Nature paper on v deep whole-genome sequencing of serial ctDNA and met tissue. @cherberts1, Matti, Joonatan et al applied new methods to give fascinating insight into temporal #ProstateCancer clonal complexity and evolution of resistance. 1/7 nature.com/articles/s4158…

So many to thank that played an outsized role in making this possible. Special mention to close friends in @ResearchWyatt lab for keeping me level-headed for last 2-3 years, @VanProstateCtr for providing a home away from home, @ANZUPtrials for bridging my return home through…

Here's our latest, led by Drs. Riaz Gillani & @RyanLCollins13 - we studied a type of inherited genetic event (structural variants) + risk of developing certain cancers in kids: @DanaFarberNews @DFCIPopSci @BostonChildrens @broadinstitute @ScienceMagazine science.org/doi/10.1126/sc…

Understanding ctDNA technology applications for cancer detection and characterization. @ResearchWyatt @VanProstateCtr joins @UroDocAsh @MDAndersonNews to break down the fundamentals of cell-free DNA and how ctDNA represents the tumor-derived portion of these fragments in the…

Really honoured to get to collaborate on this @CDNCancerTrials PC-BETS study. and to present substudy G at #ASCO25 - carboplatin for mCRPC with DDR alterations detected in ctDNA (@ResearchWyatt)

Clonal hematopoiesis (CH) in the @ANZUPtrials #TheraP study @ASCO #ASCO25 presented by Asli Munzur ■ ¹⁷⁷Lu-PSMA-617: higher incidence of emergent CH compared to cabazitaxel chemotherapy ■ Most new clonal hematopoiesis mutations ¹⁷⁷Lu-PSMA-617 fall in DNA damage repair…

Substudy C of the Canadian Cancer Trials Group IND.234 PC_BETS—A phase II study of darolutamide selected by androgen-receptor ctDNA in patients with #mCRPC after prior ARPIs Study shows darolutamide has modest efficacy in #mCRPC post-ARPIs—but ctDNA AR profiling helps select…

Stunning research from @EdmondMKwan on ctDNA in theranostics: 🧬Low ctDNA predicts better response with ¹⁷⁷Lu-PSMA-617 vs. cabazitaxel chemotherapy ⚠️PTEN alterations linked to worse outcomes on cabazitaxel 🧪ATM defects tied to favorable PSMA-617 results 🩻PET quantitative…

On the eve of #ASCO25, I am delighted to share results from the correlative analyses of the @ANZUPtrials phase II TheraP study, now published in @NatureMedicine. Massive effort supported by dedicated co-investigators, coordinators, patients & families from 11 study sites across…

Hot of the press in @JournalofNucMed ... with 10 years experience in Lutetium-177 PSMA radioligand therapy we describe a 1.3% incidence of myelodysplasia. We deep dive on each case with remarkable findings. One patient who participated in the @ANZUPtrials #TheraP trial had…

Elegant presentation from @ResearchWyatt on the evolution of ctDNA detection and characterization! Session chaired by @DanaFarber_GU's @OncoBellmunt and @BartsECMC 's @b_szabados #GU25 @ASCO @OncoAlert @OncLive

🔥 ctDNA Testing: Smoke Detector vs. Fire Investigation! 🔥 Nice analogy by @ResearchWyatt 🧬🧬🧬Not all ctDNA tests serve the same purpose! Some detect cancer early (like a smoke detector), while others characterizetumor properties to guide treatment (like a fire…

Here is a direct link to the paper rdcu.be/d5puQ

Link in the initial post is broken ! nature.com/articles/s4146…

Our paper out today in @NatureComms analyzed plasma from the phase 3 @ALLIANCE_org A031201 trial using the AR-ctDETECT assay. Patients positive for circulating tumor DNA had poor overall survival despite treatment with potent AR inhibitors. rdcu.be/d28wf

The last time Felix stood on our stage, after a beautiful talk by @mishabeltran & intro by @AminaZoubeidi 💔💔💔 vimeo.com/1037583309/b7d…

How does AR activation affect gene expression? Our new paper shows it’s less about creating new loops and more about amplifying contact frequency in existing ones. Explore in @NatureComms (rdcu.be/dYYOL) Tweetorial below: #AR #Epigenetics #prostatecancer